Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - ImVision Therapeutics Inc. - Exhibit 10.22

EXHIBIT 10.22 

IMVISION THERAPEUTICS INC.
Feodor-Lynen Strasse 5,
Hanover, Germany
Tel: 011 49 511 53 88 96-76
Fax: 011 49 511 53 88
96-66 

February 7, 2007 

DEBONDO CAPITAL LIMITED
27 New Bond Street
London
W1S 2RH 
United Kingdom 

Dear Sirs: 

	
      Consulting Services Agreement dated June 30, 2006 (the
      “Consulting Agreement’) between ImVisioN Therapeutics Inc.
      (the “Company”) and DeBondo Capital Limited (“DeBondo Capital”)
      

We write further to the Consulting Agreement and following
events: 

	
  the effectiveness of the registration statement on Form SB-2 (the “Initial
  Registration Statement”) filed by the Company with the United States
  Securities and Exchange Commission (the “SEC”) pursuant to the United States
  Securities Act of 1933 (the “1933 Act”); 

  
	
  the determination by the Company to delay the public trading of the
  Company’s common stock on the NASD OTC Bulletin Board as a result in the
  postponement of the commencement of clinical trials of the IVN 201 product
  candidate resulting from a delay in manufacturing; and 

  
	
  the determination by the Company to amend the primary offering qualified by
  the Initial Registration Statement to be an offering of 10,000,000 shares of
  common stock at a price of $0.40 per share (the “Amended Offering”) and to
  file a post-effective amendment to the Initial Registration Statement to
  reflect the amended offering (the “Post-Effective Amendment”). 

Further to our discussions, we confirm our agreement as
follows: 

	
  the Consulting Agreement is hereby terminated and of no further force or
  effect; 

  
	
  subject to full execution and delivery of the Amendment Agreement, as
  defined below, the Company will pay to DeBondo Capital the balance of the EUR
  130,000 cash fee payable under the Consulting Agreement as follows: (i) EUR
  30,000 as soon as possible upon execution of this Agreement and by no later
  than February 28, 2007 in any event, and (ii) the balance of EUR 100,000 upon
  the completion of sales of not less than $1,000,000 further to the Amended
  Offering. DeBondo Capital will have no obligation to return any portion of the
  cash fee paid under the Consulting Agreement to date or the balance to be paid
  under this agreement. The Company agrees that other than the completion of the
  Form 211 filing with Westminster Securities, DeBondo Capital is not required
  to provide any further services or consideration with respect to these cash
  payments; 

  
	
  subject to full execution and delivery of the Amendment Agreement, as
  defined below, the options granted to DeBondo Capital under the Consulting
  Agreement to purchase shares of the Company’s common stock (the “Option
  Shares”), including the options to purchase shares at prices of $0.125, $0.250
  and $0.35 per share, are hereby terminated and of no further force of effect;
  

  
	
  the Company and DeBondo Capital will enter into a separate amendment (the
  “Amendment Agreement”) to the restricted stock purchase agreement dated June
  30, 2006 between the 

Company and DeBondo Capital regarding the
  500,000 shares of the Company’s common stock owned by DeBondo Capital in the
  form attached hereto as Schedule A. The Company agrees that DeBondo is not
  required to provide any further services or consideration with respect to
  these shares and that DeBondo Capital’s rights to these shares will be
  governed solely by the Amendment Agreement; 

  	
  the Post-Effective Registration Statement will not include any of the
  Option Shares or any of the 500,000 shares held by DeBondo Capital; 

  
	
  DeBondo Capital will have no obligation to undertake and pay for any
  further professional services relating to the maintenance of the Company’s
  reporting obligations under the Securities Exchange Act or the public trading
  of the Company’s common stock on the OTC Bulletin Board or to provide any
  marketing services on behalf of the Company. With respect to professional
  services arranged for and paid for by DeBondo Capital on behalf of the Company
  to date, the Company will have no obligation to reimburse DeBondo Capital for
  any such expenses other than expenses that have been paid by DeBondo Capital
  and relate to professional services performed after December 12, 2006, being
  the date of effectiveness of the Company’s Form SB-2 registration statement;
  and 

  
	
  without imposing any obligation on DeBondo Capital to arrange for any
  financing of the Company, the Company will grant to DeBondo Capital an option
  to purchase additional securities of the Company in the event that DeBondo
  Capital identifies and introduces one or more investor(s) to the Company who
  purchase securities from the Company in an equity offering, subject to
  compliance by DeBondo Capital with all securities laws, including laws
  relating to broker-dealer registration under United States securities laws.
  The option granted will be an option to purchase a number of securities equal
  to 40% of the securities purchased by the investor identified and introduced
  by DeBondo Capital at a price equal to 50% of the purchase price paid by the
  investor. The option shall be exercisable for a period expiring on the date
  that is 180 days from the date that the Company’s common stock becomes traded
  on the OTC Bulletin Board. The Company agrees to include the registration of
  the resale by DeBondo Capital of the shares issuable upon exercise of any
  options granted in connection with any offering on any registration statement
  filed by the Company with the Securities and Exchange Commission that
  qualifies the resale by the investors who participated in the offering of the
  securities they acquired or have the right to acquire as a result of
  participation in the offering. 

  
	
  this agreement, upon execution by DeBondo Capital, will be legally binding
  and will replace and supersede our prior discussions and correspondence
  regarding these matters. 

Please execute and return a copy of this letter to confirm your
agreement. 

Yours sincerely, 

ImVisioN Therapeutics Inc.

	Per: 	 /s/ Martin Steiner 	
	Dr. Martin Steiner, President and CEO
  

	Accepted and agreed this 7th day
      of February, 2007. 
	 
	DEBONDO CAPITAL LIMITED 

	 	 	 
	Per: 	/s/ Ulrik DeBo	 
	                 	Authorized
      Signatory 	 

- 2 - 

SCHEDULE A 

Form of Amendment Agreement to Restricted Stock Purchase
Agreement 

- 3 -Filed by Automated Filing Services Inc. (604) 609-0244 - ImVision Therapeutics Inc. - Exhibit 10.23

EXHIBIT 10.23 

AMENDMENT TO

RESTRICTED STOCK PURCHASE AGREEMENT 

THIS AGREEMENT is made effective as of February 7, 2007.

BETWEEN: 

IMVISION THERAPEUTICS INC., a
Nevada corporation with an 
address at Feodor-Lynen Str. 5, 30625, Hannover,
Germany

(the “Corporation”) 

AND: 

The Undersigned Shareholder of the
Corporation 

(the “Shareholder”)

WHEREAS: 

(A)      The Shareholder has purchased
that number of shares of the Corporation’s common stock set forth on the
execution page to this Agreement at a price of $0.001 per share (the “Shares”)
as one of the nominees of DeBondo Capital Limited, namely DeBondo Capital
Limited (Beneficial Owner: Ulrik DeBo), Thomas Wittenborg, Chelmer Consulting
Corp. (Beneficial Owner: Darren Devine), Joachim Bondo and Carsten Ruehe
(collectively, the “DeBondo Nominees”). 

(B)      The Shareholder and the
Corporation entered into a restricted stock agreement dated June 30, 2006 (the
“Restricted Stock Purchase Agreement”) whereby the Shareholder agreed that the
Corporation has the right to repurchase the Shares in the event that the
Corporation’s common stock does not become eligible for trading on the NASD OTC
Bulletin Board by March 31, 2007. 

(C)      In accordance with the
Restricted Stock Purchase Agreement, the Shares have remained in escrow (the
“Escrow”) since June 30, 2006. 

(D)      The Shareholder and the
Corporation entered into an agreement dated November 7, 2006 whereby the
Corporation agreed that upon release of the Shares from Escrow in accordance
with the terms and conditions of the Restricted Stock Purchase Agreement, the
Corporation would file a registration statement with the Securities and Exchange
Commission in order to register the resale by the Shareholder of 500,000 Shares
under the 1933 Act upon receipt of a written demand for registration from the
Shareholder (the “Registration Rights Agreement”). 

(E)      The Corporation has
determined to delay the public trading of the Corporation’s common stock on the
NASD OTC Bulletin Board as a result in the postponement of the commencement of
clinical trials of the IVN 201 product candidate resulting from a delay in
manufacturing. 

(F)      The Shareholder and the
Corporation have agreed to entered into this Agreement in order to replace and
supersede the Restricted Stock Purchase Agreement and to terminate the
Registration Rights Agreement. 

THIS AGREEMENT WITNESSES THAT the Parties, intending to
be legally bound, covenant and agree as follows: 

- 2 - 

Escrow 

1.1      The Shares held by the
Corporation in Escrow in accordance with the terms of the Restricted Stock
Purchase Agreement will be released from Escrow as follows: 

(a)      50%
of the Shares (the “Released Shares”) will be released from the Escrow upon
execution of this Agreement; and 

(b)      the
remaining 50% of the Shares (the “New Escrow Shares”) will continue to be held
in Escrow (the “New Escrow”) on the terms and subject to the conditions of this
Agreement for a period (the “New Escrow Period”) expiring on the earlier of: (i)
the date that the Corporation’s common stock becomes eligible for trading on the
NASD OTC Bulletin Board, being the date that a stock symbol has been assigned by
NASD and a NASD member market maker has published a bid and ask price for the
Corporation’s common stock (the “Vesting Event”); and (ii) January 31, 2008.

Restrictions on Ownership of the New Escrow Shares Pending
Vesting

1.2      During the New Escrow Period,
the Shareholder agrees: 

     (a)      the
Shareholder will not sell, transfer, pledge, assign or otherwise dispose of the
New Escrow Shares or an interest in the New Escrow Shares; and 

     (b)      the
certificates representing the New Escrow Shares will be held by the Corporation
in trust pending release in accordance with this Agreement. 

Restrictions on Sale of the Released Shares

1.3      During the period from the
date of this Agreement until the earlier of the achievement of the Vesting Event
or January 31, 2008, the Shareholder agrees with respect to the Released Shares:

     (a)      the
Shareholder will not sell any of the Released Shares except in a transaction
whereby the number of Released Shares sold, when combined with shares
concurrently being sold by other DeBondo Nominees as part of the same
transaction and to the same purchaser, is not less than 500,000 shares of the
Corporation’s common stock; and 

     (b)    
 prior to and as a condition of the completion of any proposed sale of the
Released Shares (a “Proposed Sale”), the Shareholder will offer all shares
proposed to be sold to Nextech Venture LP (“Nextech Venturs”), or any
replacement designee of the Corporation, on a right of first refusal basis (the
“Right of First Refusal Offer”) as follows: (i) the Right of Refusal Offer will
be on the same terms and conditions, including as to price and consideration, of
the Proposed Sale, (ii) any Proposed Sale will be subject to the condition that
Nextech Venture will not have exercised its right of first refusal, (iii) the
Shareholder will give notice to Nextech Venture of the Right of First Refusal
Offer, together with all terms and conditions of such offer, at least 10
business days prior to the proposed completion date of any Proposed Sale, (iv)
Nextech Venture will have 5 business days from the date of receipt of the Right
of First Refusal Offer in which to accept or reject the Offer, (v) if Nextech
Venture accepts the Right of First Refusal Offer, then the shares will be sold
to Nextech Venture on the terms and conditions of the offer, provided that this
sale will complete within 15 business days of Nextech Venture’ acceptance, (vi)
if Nextech Venture does not accept the Right of First Refusal Offer, then the
Shareholder may proceed with the Proposed Sale, provided that if the Proposed
Sale does not complete within 90 days of the date of original notice of the
Right of First Refusal, then the Shareholder must again deliver a Right of First

- 3 - 

Refusal Offer with respect to any sale. The Shareholder agrees
that such rights are granted as consideration for the release of the Released
Shares and that such rights may be enforced by the Corporation or by Nextech
Venture as a third party beneficiary. 

Vesting 

1.4      The Shareholder’s right to a
release of the New Escrow Shares will vest on the Vesting Event in the event
that the Vesting Event takes place prior to January 31, 2008. In the event that
the Vesting Event does not take place prior to January 31, 2008, then the
Shareholder will be entitled to a release of the New Escrow Shares on January
31, 2008, notwithstanding that the Vesting Event may not have taken place. Upon
achievement of the earlier of the Vesting Event or January 31, 2008, the
certificates representing the New Escrow Shares will be released by the
Corporation to the Shareholder and the New Escrow will forthwith terminate and
be of no further force or effect.

Corporation Right of Repurchase 

1.5      The terms and conditions of
this Agreement supersede and replace the terms and conditions of the Restricted
Stock Purchase Agreement. 

Termination of Registration Rights 

1.6      The Registration Rights
Agreement and the rights of the Shareholder under the Registration Rights
Agreement are hereby terminated and no further force or effect.

Governing Law and Attornment 

1.7      This Agreement will be
exclusively governed by, and interpreted and construed in accordance with, the
laws prevailing in the State of Nevada. 

Time of Essence 

1.8      Time is of the essence in the
performance of each obligation under this Agreement. 

Entire Agreement 

1.9      This Agreement constitutes
the entire agreement between the Parties and supersedes all prior agreements and
understandings, oral or written, by and between any of the Parties with respect
to the subject matter hereof. 

Further Assurances 

1.10      The Parties will with
reasonable diligence, do all such things and provide all such reasonable
assurances as may be required to consummate the transactions contemplated by
this Agreement, and each Party will provide such further documents or
instruments required by the other Party as may be reasonably necessary or
desirable to give effect to the purpose of this Agreement. 

- 4 - 

Counterparts 

1.11      This Agreement may be
executed in any number of counterparts, in original form or by facsimile, each
of which will together, for all purposes, constitute one and the same
instrument, binding on the parties, and each of which will together be deemed to
be an original, notwithstanding that each party is not a signatory to the same
counterpart. 

IN WITNESS WHEREOF the Parties have duly executed this
Agreement effective as of the day and year first above written. 

IMVISION THERAPEUTICS INC. 

	Per: 	 	 
	                   	 Authorized Signatory 	 

	Number of Shares Held: 	Shares 
	  	  
	Signature of Shareholder or Authorized 	  
	Signatory of Shareholder: 	 
    
	  	  
	Name of Authorized Signatory of 	  
	Subscriber (if Subscriber is not an 	  
	individual): 	 
    
	  	  
	Title of Authorized Signatory of 	  
	Shareholder (if Shareholder is not an 	  
	individual): 	 
    
	  	  
	  	  
	Name of Shareholder: 	 
    
	  	  
	Address of Shareholder:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]